BMS Hopes Turning Point Buyout Will Fare Better Than Roche’s Ignyta Acquisition

 
• By Joseph Haas
  
Bristol Myers Squibb
Bristol Myers Squibb makes big precision oncology play in Turning Point buyout • Source: Bristol Myers Squibb (ROBERT BRUSCHINI IM GES LLC)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business